Characteristics of Metabolically Dysfunctional Associated Fatty Liver Disease (MAFLD) patients in Al Rajhi Hospital Nutrition Clinic: A Cross-sectional Study | ||||
| Journal of Current Medical Research and Practice | ||||
| Volume 10, Issue 3, July 2025, Page 129-136 PDF (837.89 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/jcmrp.2024.315865.1122 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Yusuf S. Amry  ; Magda Shehata Hassan; Sherif Ibrahim Kamel; Mohammed Ahmed Medhat
| ||||
| Department of Tropical Medicine and Gastroenterology, Faculty of Medicine, Assiut University, Assiut, Egypt. | ||||
| Abstract | ||||
| Abstract: Objective: Fatty liver disease has become the most frequent chronic liver disease and the fastest-growing reason for liver transplant among waiting list registrants. Egypt is one of the top 10 nations with the prevalence of fatty liver disease. We assessed the prevalence of Metabolically Dysfunctional Associated Fatty Liver Disease (MAFLD) among patients presenting to the nutrition clinic in our hospital between June 2022 and June 2023. Design: In this cross-sectional study, we collected a group of patients attending to Al Rajhi hospital nutrition clinic in Assiut. Our primary outcome was screening for MAFLD among those patients. Secondary objectives included assessing the degree of fibrosis and steatosis using FibroScan with CAP, the rate of obesity, diabetes, and hyperlipidaemia, and the proportion of patients with other related chronic liver disease (CLD). Results: Of 1120 patients evaluated, 365 (32.6%) had MAFLD. The mean age of MAFLD patients was 45. (53.3%) were females. Mean fibrosis reading was 6.52 (kPa), and (≥F2) was noted in (23.5%) of MAFLD patients. Mean CAP measurement was 263.45 (dB/m), and S3 (severe steatosis) was reported in 88 (24.1%) MAFLD patients. DM was noted in 17 (4.5%) of MAFLD patients, obesity was noted in 326 (89.3%), and hypertriglyceridemia was reported in 95 (26%). Hepatitis B surface antigen was positive in 20 (5.5%), and Hepatitis C antibodies were positive in 123 (33.7%) of MAFLD patients. Conclusion: In this cohort of patients, MAFLD was noted in 1 in every 3 patients. Most of those were obese female patients. This is nearly similar to the previous data with the previous nomenclature, NAFLD. | ||||
| Keywords | ||||
| Keywords: Fatty liver; MAFLD; FibroScan; Nafld; Obesity | ||||
|
Statistics Article View: 1 |
||||
